aldosterone receptor antagonist (aldosterone antagonist)

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

Drug interactions

More general terms

More specific terms

Additional terms

References

  1. Rossing K et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. A randomized, double-masked, cross-over study. Diabetes Care 2005 Sep; 28:2106-12. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16123474
  2. 2.0 2.1 2.2 Deprecated Reference
  3. 3.0 3.1 Desai AS, Vardeny O, Claggett B et al Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/ Valsartan Compared With Enalapril. A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. Published online November 14, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27842179 <Internet> http://jamanetwork.com/journals/jamacardiology/article-abstract/2583456
    Ezekowitz JA Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. JAMA Cardiol. Published online November 14, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27842180 <Internet> http://jamanetwork.com/journals/jamacardiology/article-abstract/2583455
  4. 4.0 4.1 Dahal K, Hendrani A, Sharma SP et al Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure. A Systematic Review and Meta-analysis. JAMA Intern Med. Published online May 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29799995 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2681656
    Pitt B, Zannad F. Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction JAMA Intern Med. Published online May 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29799990 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2681651
  5. NEJM Knowledge+